Ingrid Delaet Sells 272 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Stock

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) insider Ingrid Delaet sold 272 shares of the company’s stock in a transaction on Tuesday, December 31st. The shares were sold at an average price of $138.10, for a total transaction of $37,563.20. Following the completion of the sale, the insider now directly owns 2,507 shares of the company’s stock, valued at $346,216.70. This trade represents a 9.79 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Ingrid Delaet also recently made the following trade(s):

• On Tuesday, December 17th, Ingrid Delaet sold 1,091 shares of Neurocrine Biosciences stock. The shares were sold at an average price of $135.00, for a total transaction of $147,285.00.

Neurocrine Biosciences Trading Up 0.2 %

NASDAQ NBIX opened at $138.10 on Friday. Neurocrine Biosciences, Inc. has a 12 month low of $110.95 and a 12 month high of $157.98. The stock’s fifty day moving average price is $128.11 and its 200-day moving average price is $130.81. The stock has a market cap of $13.98 billion, a P/E ratio of 37.02 and a beta of 0.33.

Wall Street Analyst Weigh In

NBIX has been the subject of a number of research reports. William Blair reaffirmed an “outperform” rating on shares of Neurocrine Biosciences in a research note on Monday, December 16th. Royal Bank of Canada dropped their price target on shares of Neurocrine Biosciences from $136.00 to $133.00 and set a “sector perform” rating for the company in a research report on Friday, October 4th. BMO Capital Markets dropped their price target on shares of Neurocrine Biosciences from $128.00 to $114.00 and set a “market perform” rating for the company in a research report on Thursday, October 17th. Piper Sandler reissued an “overweight” rating and set a $160.00 price target on shares of Neurocrine Biosciences in a research report on Monday, December 23rd. Finally, Needham & Company LLC reissued a “hold” rating on shares of Neurocrine Biosciences in a research report on Friday, December 20th. Five investment analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $166.29.

Institutional Trading of Neurocrine Biosciences

A number of institutional investors and hedge funds have recently bought and sold shares of NBIX. State Street Corp grew its holdings in shares of Neurocrine Biosciences by 11.7% during the third quarter. State Street Corp now owns 5,148,293 shares of the company’s stock valued at $593,186,000 after buying an additional 539,936 shares during the last quarter. 1832 Asset Management L.P. lifted its position in Neurocrine Biosciences by 1,370.7% in the 2nd quarter. 1832 Asset Management L.P. now owns 541,200 shares of the company’s stock valued at $74,507,000 after acquiring an additional 504,400 shares in the last quarter. Los Angeles Capital Management LLC boosted its stake in Neurocrine Biosciences by 639.6% during the 3rd quarter. Los Angeles Capital Management LLC now owns 420,748 shares of the company’s stock valued at $48,479,000 after purchasing an additional 363,863 shares during the last quarter. AQR Capital Management LLC increased its holdings in shares of Neurocrine Biosciences by 23.0% in the 2nd quarter. AQR Capital Management LLC now owns 1,223,055 shares of the company’s stock worth $166,959,000 after purchasing an additional 228,444 shares in the last quarter. Finally, Renaissance Technologies LLC raised its stake in shares of Neurocrine Biosciences by 9.6% in the second quarter. Renaissance Technologies LLC now owns 2,468,146 shares of the company’s stock worth $339,790,000 after purchasing an additional 216,500 shares during the last quarter. 92.59% of the stock is currently owned by institutional investors.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.